NEW DELHI: Haleon, formerly GSK Consumer Healthcare, will invest approximately Rs 2,000 crore (£175 million) to establish its first manufacturing facility in India, highlighting the country's status as one of the company's fastest-growing markets globally.
Strategic Investment in Madhya Pradesh
The greenfield facility will be located at Pithampur in Madhya Pradesh. This significant investment in India's consumer health sector reinforces Haleon's long-term commitment to the country as a strategic growth market, the company stated.
Currently, Haleon relies on third-party contract manufacturers in India. This new facility will be its first owned manufacturing plant in the country and the first in South Asia.
Focus on Oral Health and 'Make in India'
The plant will primarily focus on oral-health products. According to Kedar Lele, CEO India and President India Subcontinent at Haleon, the facility will support the government's 'Make in India' vision, strengthen supply chain resilience, drive domestic value addition, and facilitate exports to other key markets.
This investment will also help Haleon achieve its goal of reaching one billion more consumers by 2030, including 300 million in India.
Future-Ready Manufacturing Capabilities
The facility is designed based on Haleon's new global advance blueprint and will feature future-ready automated manufacturing capabilities. It is expected to become operational by 2029–30, enabling the company to meet growing demand in both domestic and international markets.
In India, Haleon's portfolio includes oral health, digestive health, pain relief and respiratory (PRS), and vitamins, minerals, and supplements. Key brands include Sensodyne, Eno, Otrivin, Centrum, Iodex, and Crocin.
This investment marks a major milestone for Haleon in India, underscoring its dedication to expanding its manufacturing footprint and supporting the country's economic growth.
